Bibliography
- Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7(5):359-71
- Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007;13(18):5544s-8s
- Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009;6(10):569-79
- Dayanir V, Meyer RD, Lashkari K, Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem 2001;276(21):17686-92
- Vjoukov KP, Kaipainen A, Chilov D, A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15(7):9
- Kaipainen A, Korhonen J, Pajusola K, The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med 1993;178(6):2077-88
- Schwartz JD, Rowinsky EK, Youssoufian H, Vascular endothelial growth factor receptor-1 in human cancer. Cancer 2010;116(S4):1027-32
- Waltenberger J, Claesson-Welsh L, Siegbahn A, Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269(43):26988-95
- Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8(12):942-56
- Kearney JB, Kappas NC, Ellerstrom C, The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 2004;103(12):4527-35
- Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
- Su JL, Yen CJ, Chen PS, The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2006;96(4):541-5
- Makinen T, Veikkola T, Mustjoki S, Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001;20(17):4762-73
- Hamada K, Oike Y, Takakura N, VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood 2000;96(12):3793-800
- Matsumura K, Hirashima M, Ogawa M, Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3. Blood 2003;101(4):1367-74
- Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-7
- Boehm T, Folkman J, Browder T, O'reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390(6658):404-7
- Falm E, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42(18):3127-39
- Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 2010;46(8):1323-32
- Gille J, Heidenreich R, Pinter A, Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. Int J Cancer 2007;120(9):1899-908
- Winkler F, Kozin SV, Tong RT, Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6(6):553-63
- Bradley DP, Tessier JJ, Lacey T, Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magn Reson Imaging 2009;27(3):377-84
- Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 2006;75(1):93-109
- Ghosh S, Zheng Y, Jun X, Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin Cancer Res 1998;4(11):2657-68
- Bae D-G, Kim T-D, Li G, Anti-Flt1 Peptide, a vascular endothelial growth factor receptor 1–specific hexapeptide, inhibits tumor growth and metastasis. Clin Cancer Res 2005;11(7):2651-61
- Ponticelli S, Marasco D, Tarallo V, Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J Biol Chem 2008;283:34250-9
- Patel N, Sun L, Moshinsky D, A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. J Pharmacol Exp Ther 2003;306(3):838-45
- Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9(1):28-39
- Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules. Nature 2006;441(7092):457-62
- Garber K. Angiogenesis inhibitors suffer new setback. Nat Biotechnol 2002;20(11):1067-8
- Hoff PM, Wolff RA, Bogaard K, A phase i study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. Jpn J Clin Oncol 2006;36(2):100-3
- Scholz A, Wagner K, Welzel M, The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model. Gut 2009;58(2):261-70
- Scott E, Thomas A, Molife L, A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours. Cancer Chemother Pharmacol 2009;64(2):425-9
- Solorzano CC, Baker CH, Bruns CJ, Inhibition of Growth and metastasis of human pancreatic cancer growing in nude mice by ptk 787/zk222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 2004;16(11):359
- Langenberg MH, Witteveen PO, Lankheet NA, Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis. Neoplasia 2010;12(2):7
- Phase I Study of the oral vascular endothelial growth factor inhibitor PTK787/ZK 222584 in combination with paclitaxel in patients with advanced solid tumors. NCT00358163. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00358163?term=ptk+787&phase=0&rank=1
- A Phase I trial of docetaxel and PTK787 in metastatic breast cancer patients and recurrent or refractory gynecological cancer patients. NCT00268918. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00268918?term=ptk+787&phase=0&rank=9
- An open-label phase ii study evaluating the safety and efficacy of PTK787/ZK222584 in patients with metastatic neuroendocrine tumors that have evidence of progressive disease or an increase in disease related syndrome symptoms. NCT00590343. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00590343?term=ptk+787&phase=1&rank=1
- Banerjee S, A'hern R, Detre S, Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. Clin Cancer Res 2010;16(16):4178-87
- Los M, Roodhart JML, Voest EE. Target practice: lessons from phase iii trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007;12(4):443-50
- Li J, Zhao X, Chen L, Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 2010;10(1):529
- A Study of apatinib in patients with advanced non-squamous and non-small cell lung cancer. NCT01270386. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01270386?term=vegf+receptor+AND+cancer&phase=01&rcv_s=05%2F01%2F2010&rcv_e=05%2F14%2F2011&rank=3
- Apatinib in the treatment of advanced non-squamous non-small cell lung cancer. NCT01287962. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01287962?term=vegf+receptor+AND+cancer&phase=01&rcv_s=05%2F01%2F2010&rcv_e=05%2F14%2F2011&rank=2
- Wilmes LJ, Pallavicini MG, Fleming LM, AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007;25(3):319-27
- Sharma S, Abhyankar V, Burgess RE, A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 2010;21(2):297-304
- Schiller JH, Larson T, Ou S-HI, Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009;27(23):3836-41
- Rini BI, Wilding G, Hudes G, Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27(27):4462-8
- Fruehauf JP, Lutzky J, Mcdermott DF, Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. J Clin Oncol 2008;26(15 Suppl):9006
- Spano J-P, Chodkiewicz C, Maurel J, Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008;371(9630):2101-8
- A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer. NCT00471146. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00471146?term=NCT00471146&rank=1
- Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer. NCT00920816. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00920816?term=NCT00920816&rank=1
- Polverino A, Coxon A, Starnes C, AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66(17):8715-21
- Price TJ, Lipton L, Williams J, Safety and pharmacokinetics (PK) of AMG 706 in combination with gemcitabine for the treatment of patients (pts) with solid tumors. J Clin Oncol 2007;25(18 Suppl):14005
- Crawford J, Burris H, Stephenson J Jr, Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer. J Clin Oncol 2007;25(18 Suppl):14057
- Schwartzberg LS, Hurwitz H, Stephenson J Jr, Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2007;25(18 Suppl):4081
- Azad A, Herbertson RA, Pook D, Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta Oncol (Madr) 2009;48(4):619-21
- Boer D, Kaufman PA, White S, Primary analysis of a Phase 1b combination study of motesanib (AMG 706) with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer. Cancer Res 2009;69(2) Suppl 1:24 abstract
- An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus panitumumab plus chemotherapy in the treatment of subjects with metastatic colorectal cancer. NCT00101894. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00101894?term=NCT00101894&rank=1
- An Open-Label. Dose-Finding Study to Evaluate the Safety of AMG 706 Plus panitumumab plus gemcitabine-cisplatin in the treatment of subjects with advanced cancer. NCT00101907. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00101907?term=NCT00101907&rank=1
- A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in combination with paclitaxel and carboplatin for advanced non-squamous non-small cell lung cancer. NCT00369070. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00369070?term=NCT00369070&rank=1
- Schlumberger MJ, Elisei R, Bastholt L, Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27(23):3794-801
- A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in patients with low-grade neuroendocrine tumors. NCT00427349. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00427349?term=NCT00427349&rank=1
- A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer. NCT00460317. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00460317?term=NCT00460317&rank=1
- Investigational Drug in combination with two chemotherapy drugs in women with locally recurrent or metastatic breast cancer. NCT01349088. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01349088?term=vegf+receptor+AND+cancer&phase=01&rcv_s=05%2F01%2F2010&rcv_e=05%2F14%2F2011&rank=11
- Blumenschein GR, Reckamp K, Stephenson GJ, Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non–small cell lung cancer. Clin Cancer Res 2010;16(1):279-90
- Blumenschein GR, Kabbinavar F, Menon H, A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011 [Epub ahead of print]
- Wedge SR, Kendrew J, Hennequin LF, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389-400
- Gomez-Rivera F, Santillan-Gomez AA, Younes MN, The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin Cancer Res 2007;13(15):4519-27
- Padera TP, Kuo AH, Hoshida T, Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 2008;7(8):2272-9
- Cao C, Albert JM, Geng L, Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 2006;66(23):11409-15
- Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer. NCT01116648. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01116648?term=NCT01116648&rank=1
- A Two Part Study in Japanese patients with mCRC, consisting of an open-label phase i part to assess the safety and tolerability of AZD2171 in combination with FOLFOX followed by a phase ii, randomised, double-blind, parallel group study to assess the efficacy of AZD2171 in combination with FOLFOX. NCT00494221. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00494221?term=NCT00494221&rank=1
- A Randomized Phase II Study of Gemcitabine and Carboplatin with or without AZD2171 as first-line therapy in advanced non-small cell lung cancer. NCT00326599. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00326599?term=NCT00326599&rank=1
- A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN™) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients With Previously Untreated Metastatic Colorectal Cancer. NCT00399035. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00399035?term=NCT00399035&rank=1
- A Randomised Trial of Concurrent (With Platinum Based Chemotherapy) and maintenance cediranib in women with platinum sensitive relapsed ovarian cancer. NCT00532194. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00532194?term=NCT00532194&rank=1
- A Double Blind Randomized Trial of Cediranib Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the treatment of advanced or metastatic non-small cell lung cancer. NCT00795340. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00795340?term=NCT00795340&rank=1
- Batchelor TT, Sorensen AG, Di Tomaso E, AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95
- Potapova O, Laird AD, Nannini MA, Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006;5(5):1280-9
- Demetri GD, Van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329-38
- Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus Interferon Alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
- Michaelson D, Mcdermott DF, Atkins MB, Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. J Clin Oncol 2010;28(15 Suppl):e15076
- Burstein HJ, Elias AD, Rugo HS, Phase II Study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26(11):1810-16
- Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor. NCT01176799. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01176799?term=vegf+receptor+AND+cancer&phase=01&rcv_s=05%2F01%2F2010&rcv_e=05%2F14%2F2011&rank=1
- Socinski MA, Novello S, Brahmer JR, Multicenter, phase ii trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26(4):650-6
- Zhu AX, Sahani DV, Duda DG, Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27(18):3027-35
- Ebos JML, Lee CR, Cruz-Munoz W, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15(3):232-9
- George S, Lal R, Camidge DR, Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors. J Clin Oncol 2009;27(15S):3564
- A Phase 1 Dose Escalation Study of Daily Oral OSI-930 and Erlotinib (Tarceva) in patients with advanced solid tumors. NCT00603356. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00603356?term=osi+930&rank=2
- Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
- A Study of Pazopanib as second line therapy in patients with metastatic prostate cancer who have received prior therapy with an LHRH agonist. NCT00945477. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00945477?term=gw+786034&phase=1&rank=9
- A Randomized, Multicenter, Phase III Study comparing the combination of pazopanib and lapatinib versus lapatinib monotherapy in patients with ErbB2 Over-expressing inflammatory breast cancer. NCT00558103. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00558103?term=gw+786034&phase=23&rank=2
- A Randomized, Double-blind, Placebo-controlled Phase II-III Multi-centre Study to evaluate the effect of adjuvant Pazopanib (GW786034) Versus placebo on post-surgical disease-free survival in patients with stage I non small cell lung cancer and tumor size equal or inferior to 5 cm. NCT00775307. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00775307?term=gw+786034&phase=23&rank=3
- Iwamoto FM, Lamborn KR, Robins HI, Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 2010;12(8):855-6
- Langenberg MHG, Witteveen PO, Roodhart JM, Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clin Cancer Res 2010;16(7):2187-97
- A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in combination with chemotherapy as first-line therapy in subjects with advanced gastric cancer. NCT00952497. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00952497?term=telatinib&rank=1
- Velleca M, Brittelli D, Elkin L, Preclinical and preliminary phase 1 trial results of JI-101: a novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFR. Mol Cancer Ther 2009;8(12 Suppl 1):5
- Study of JI-101 in patients with advanced low grade endocrine tumors, ovarian cancers or K-RAS mutant colon cancers. NCT01149434. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01149434?term=vegf+receptor+AND+cancer&phase=01&rcv_s=05%2F01%2F2010&rcv_e=05%2F14%2F2011&rank=4
- A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in patients with advanced solid tumors. NCT00842335. Available from: http://clinicaltrials.gov/ct2/show/NCT00842335?term=JI-101&rank=1
- A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab (Erbitux®) Versus Placebo in Combination With Cetuximab (Erbituxreg®) in Patients With K-RAS Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma. NCT00640471. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00640471?term=bms+582664&phase=23&rank=1
- A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib. NCT01108705. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01108705?term=bms+582664&phase=23&rank=2
- A Phase Ib Multiple Ascending Dose Study to Evaluate the Safety of Brivanib in Combination With 5-Fluorouracil/Leucovorin (5FU/LV) and Brivanib in Combination With 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) in Subjects With Advanced or Metastatic Gastrointestinal Malignancies. NCT01046864. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01046864?term=bms+582664&phase=0&rank=9
- A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs Placebo in Combination With Erbitux and Irinotecan K-Ras Wildtype Subjects With Metastatic Colorectal Cancer. NCT00594984. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00594984?term=bms+582664&phase=0&rank=10
- Patel RR, Sengupta S, Kim HR, Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer 2010;46(9):1537-53
- Bello E, Colella G, Scarlato V, E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011;71(4):1396-405
- Ogino H, Hanibuchi M, Kakiuchi S, E7080, a multiple tyrosine kinase inhibitor, suppresses hematogenous multiple organ metastases of lung cancer cells with non-mutated epidermal growth factor receptor. Mol Cancer Ther 2011;10(7):1218-28
- Loriot Y, Mordant P, Dorvault N, BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation. Br J Cancer 2010;103(3):347-53
- A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMAtrade) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). NCT00404924. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00404924?term=6474+egfr&rank=1
- A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimtareg®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC. NCT00418886. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00418886?term=zd+6474&phase=23&rank=1
- Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
- Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
- Garofalo A, Goossens L, Lemoine A, Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer. J Enzyme Inhib Med Chem 2010;25(2):158-71
- Natale RB, Bodkin D, Govindan R, Vandetanib versus gefitinib in patients with advanced non–small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009;27(15):2523-9
- Sarkar S, Mazumdar A, Dash R, ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 2010;9(8):592-693
- A Phase I Study of ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer. NCT00496665. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00496665?term=zd+6474&phase=0&rank=5
- Phase I Study of ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer. NCT00436072. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00436072?term=zd+6474&phase=0&rank=11
- Phase I/II Study of ZD6474 (Vandetanib) with radiation therapy and concomitant and adjuvant temozolomide in patients with newly-diagnosed glioblastoma. NCT00441142. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00441142?term=zd+6474&phase=1&rank=1
- An International, Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Versus Placebo in Subjects With Unresectable, Locally Advanced or Metastatic Medullary Thyroid Cancer. NCT00410761. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00410761?term=zd+6474&phase=1&rank=2
- A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in combination with gemcitabine versus gemcitabine plus vandetanib matching placebo in subjects with advanced biliary tract cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma). NCT00753675. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00753675?term=zd+6474&phase=1&rank=5
- Yokoi K, Thaker PH, Yazici S, Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005;65(9):3716-25
- Kuwai T, Nakamura T, Sasaki T, Targeting the EGFR. VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis 2008;25(4):477-89
- Rebhun RB, Langley RR, Yokoi K, Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia 2006;8(9):747-57
- Deng M, Huang H, Jin H, The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats. Invest New Drugs 2011;29(4):593-606
- Available from: http://www.clinicaltrials.gov/ct2/homeClinicalTrials.gov 2010
- Juengel E, Engler J, Mickuckyte A, Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. BJU Int 2010;105(4):549-57
- Evans AH, Pancholi S, Farmer I, EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. Br J Cancer 2010;102(8):1235-43
- Wan PTC, Garnett MJ, Roe SM, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
- Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
- Patel NS, Muneer A, Blick C, Targeting vascular endothelial growth factor in renal cell carcinoma. Tumor Biol 2009;30(5-6):292-9
- A Phase III, Multi-center, Placebo-controlled Trial of Sorafenib (BAY43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens. NCT00863746. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00863746?term=NCT00863746&rank=1
- A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer. NCT00984282. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00984282?term=nct00984282&rank=1
- Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas. NCT00541021. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00541021?term=nct00541021&rank=1
- A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel, and BAY 43-9006 Versus Carboplatin, Paclitaxel, and Placebo in Patients With Unresectable Stage III or IV Melanoma. NCT00110019. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00110019?term=nct00110019&rank=1
- Hormone Blockade in Combination With Targeted Agents. NCT01197170. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01197170?term=vegf+receptor+AND+cancer&phase=01&rcv_s=05%2F01%2F2010&rcv_e=05%2F14%2F2011&rank=8
- Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment. NCT01262482. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01262482?term=vegf+receptor+AND+cancer&phase=01&rcv_s=05%2F01%2F2010&rcv_e=05%2F14%2F2011&rank=13
- Sun W, Powell M, O'dwyer PJ, Phase II Study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28(18):2947-51
- A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma. NCT01308723. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01308723?term=vegf+receptor+AND+cancer&phase=01&rcv_s=05%2F01%2F2010&rcv_e=05%2F14%2F2011&rank=5
- Lam ET, Ringel MD, Kloos RT, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28(14):2323-30
- Angevin E, Lin C, Pande AU, A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results. J Clin Oncol 2010;28(15 Suppl):3057
- Andre F, Baselga J, Ellis MJ, Study CTKI258A2202: a multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer. J Clin Oncol 2010;28(15 Suppl):TPS122
- Reck M. BIBF 1120 for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs 2010;19(6):789-94
- A Randomized Double-blind Multicenter Phase III Trial of BIBF 1120 Plus Pemetrexed vs. Pemetrexed/Placebo in advanced or recurrent non small cell lung cancer patients after failure of first line therapy. NCT00806819. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00806819?term=bibf+1120&phase=23&rank=1
- Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer. NCT01015118. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01015118?term=bibf+1120&phase=23&rank=2
- A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer. NCT01024920. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01024920?term=bibf+1120&phase=1&rank=3
- A Phase I-II Study of BIBF 1120 and FOLFOX Compared to Bevacizumab and FOLFOX in First Line Metastatic Colorectal Cancer Patients. NCT00904839. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00904839?term=bibf+1120&phase=1&rank=1
- A Multicenter, Open Label, Phase I/ II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Oral Sorafenib for Advanced Hepatocellular Carcinoma Patients.: NCT01004003. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01004003?term=bibf+1120&phase=1&rank=7
- Dose Escalation Study of Concomitant BIBF 1120 + BIBW 2992 in Patients With Advanced Solid Tumours.: NCT00998296. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00998296?term=bibf+1120&phase=0&rank=1
- Dose Escalation trial of BI 6727 in combination with BIBF 1120. NCT01022853. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01022853?term=bibf+1120&phase=0&rank=6
- Cripe L, Mcguire W, Wertheim M, Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM). J Clin Oncol 2007;25(18 Suppl):3591
- A Maintenance Study Evaluating the Long Term Safety of XL999 administered intravenously to subjects with advanced malignancies previously enrolled in other XL999 Studies. NCT00955084. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00955084?term=xl+999&rank=1
- Qian F, Engst S, Yamaguchi K, Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69(20):8009-16
- Zillhardt M, Park S-M, Romero IL, Foretinib (GSK1363089), an orally available multi-kinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res 2011;17(12):4042-51
- Liu L, Shi H, Liu Y, Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-Coactivated tumor cells. Mol Cancer Ther 2011;10(3):518-30
- Eder JP, Shapiro GI, Appleman L, A Phase I Dose-Escalation Study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity of foretinib. Clin Cancer Res 2010;16(13):3507-16
- Study of GSK1363089 in Metastatic Gastric Cancer. NCT00725712. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00725712?term=foretinib&rank=5
- A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC). NCT00726323. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00726323?term=foretinib&rank=4
- A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (IND197). NCT01147484. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01147484?term=foretinib&rank=9
- Luttun A, Tjwa M, Moons L, Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:10
- Wu Y, Zhong Z, Huber J, Anti-Vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006;12(21):6573-84
- Koukourakis MI, Giatromanolaki A, Sheldon H, Phase I/II Trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. Clin Cancer Res 2009;15(22):7069-76
- Shaheen RM, Ahmad SA, Liu W, Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85(4):584-9
- Kozin SV, Boucher Y, Hicklin DJ, Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001;61(1):39-44
- Dias S, Hattori K, Heissig B, Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001;98(19):10857-62
- Posey JA, Ng TC, Yang B, A Phase I Study of Anti-Kinase Insert Domain-containing Receptor Antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003;9(4):1323-32
- A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer. NCT00152477. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00152477?term=NCT00152477&rank=1
- A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy. NCT00917384. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00917384?term=NCT00917384&rank=1
- A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer. NCT00703326. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00703326?term=NCT00703326&rank=1
- A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH). NCT01140347. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01140347?term=NCT01140347&rank=1
- A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy. NCT01168973. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01168973?term=NCT01168973&rank=1
- An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B in Combination With 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in patients with metastatic colorectal cancer. NCT00862784. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00862784?term=NCT00862784&rank=1
- Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in patients with metastatic malignant melanoma. NCT00533702. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00533702?term=IMC1121B&phase=1&rank=2
- Phase II Single Arm Study of IMC-1121B in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. NCT00515697. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00515697?term=IMC1121B&phase=1&rank=3
- A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy. NCT00683475. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00683475?term=IMC1121B&phase=1&rank=5
- An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme. NCT00895180. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00895180?term=IMC1121B&phase=1&rank=8
- A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. NCT00721162. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00721162?term=IMC1121B&phase=1&rank=10
- Krishnamurthi SS, Lorusso PM, Goncalves PH, Phase 1 study of weekly anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody IMC-18F1 in patients with advanced solid malignancies. J Clin Oncol 2008;26(15 Suppl):14630
- An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With IMC 1121B or IMC 18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy. NCT01111604. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01111604?term=IMC+18F1&rank=2
- Mamluk R, Carvajal IM, Morse BA, Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. mAbs 2010;2(2):199-208
- Dineen S, Sullivan L, Beck A, The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2008;8(1):352
- Sweeney CJ, Chriorean EG, Mita MM, Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST). J Clin Oncol 2008;26(15 Suppl):3523
- Tolcher AW, Sweeney CJ, Papadopoulos K, Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 2011;17(2):363-71
- Schiff D, Reardon DA, Kesari S, Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM). J Clin Oncol 2010;28(15 Suppl):2011
- Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme. NCT00768911. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00768911?term=NCT00768911&rank=1
- A Phase 1, Escalating Dose Study of CT-322, a VEGFR-2 Antagonist, as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma. NCT00374179. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00374179?term=NCT00374179&rank=1
- A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer. NCT00851045. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00851045?term=NCT00851045&rank=1
- A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology. NCT00850577. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00850577?term=NCT00850577&rank=1
- Tvorogov D, Anisimov A, Zheng W, Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010;18(6):630-40
- A Phase II, Open-Label, Multicenter Trial of Angiozyme in Subjects With Metastatic Renal Cell Cancer. NCT00021021. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00021021?term=angiozyme&rank=1
- Kashani-Sabet M. Non-viral delivery of ribozymes for cancer gene therapy. Expert Opin Biol Ther 2004;4(11):1749-55
- Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010;106(1):21-34
- Staton C, Yang Z, Reed M, Brown N. Bevacizumab resistance in breast cancer: are neuropilins the key? Breast Cancer Res 2008;10(Suppl 2):P75
- Li JL, Harris AL. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci 2009;14:16
- Sallinen H, Anttila M, Grohn O, Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice. Cancer Gene Ther 2011;18(2):100-9
- Chae S-S, Kamoun WS, Farrar CT, Angiopoietin-2 interferes with Anti-VEGFR2–induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010;16(14):3618-27
- Roberts N, Kloos B, Cassella M, Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006;66(5):2650-7
- Graepler F, Verbeek B, Graeter T, Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 2005;41(4):879-86
- Mahasreshti PJ, Navarro JG, Kataram M, Adenovirus-mediated Soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001;7(7):2057-66
- Goldman CK, Kendall RL, Cabrera G, Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998;95(15):8795-800
- Fragoso R, Pereira T, Wu Y, VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 2006;107(4):1608-16
- Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004;25(7):387-95
- Birk DM, Barbato J, Mureebe L, Chaer RA. Basic science review: current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovascular Surg 2009;42(6):517-30
- Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22(4):201-7